A Paywalled Abrocitinib Study Promises Data on Elderly Patients' Appetite. The Evidence Behind That Claim Is Still Locked

A study titled "Abrocitinib in elderly patients with moderate-to-severe atopic dermatitis: A real-world study of clinical outcomes and appetite changes" went up on ScienceDirect on October 2, 2026, credited to Yu-ting Gan, Shi Yan, Qing-chun Diao, Bing-jun Shi, Yi Liu, Xun Zhou and Feng-lin Chen in the Journal of the American Academy of Dermatology. The full text sits behind a paywall, which means the headline itself, not the data, is the only thing currently verifiable about what this paper claims.

That headline is unusual on its face. Across the published trial and real-world literature on abrocitinib, a JAK inhibitor marketed by Pfizer as Cibinqo, appetite has never been a standalone outcome measure. Standard adverse-event lists from trials and registries report nausea, headache, acne, elevated creatine kinase, and herpes zoster or upper respiratory infections. Nausea is occasionally noted to ease when the drug is taken with food, but no prior abrocitinib paper singles out appetite as a metric worth its own subtitle, which raises the first question a reader can't yet answer: is this a new adverse signal, a nutritional-screening finding tied to frailty in older patients, or simply a reframing of known gastrointestinal effects through a geriatric lens.

The timing matters. A letter also published in the Journal of the American Academy of Dermatology in early 2026, "Abrocitinib safety in geriatric patients: The need for a holistic assessment," by Datli Yakaryilmaz, Türkmen and Altunişik, carries the DOI 10.1016/j.jaad.2026.02.126 and uses keywords including frailty, geriatric assessment and malnutrition. Its presence in the same journal, on the same population, in the same year, suggests a live editorial conversation about whether abrocitinib's safety in elderly patients can be judged from a standard adverse-event table at all, or whether it requires the kind of nutritional and frailty screening geriatricians use for other drug classes. Without the cited paper's own methods section, it is impossible to say whether this real-world study is the subject of that letter, a response to it, or an unrelated parallel effort.

The regulatory backdrop explains why any elderly-specific abrocitinib data draws scrutiny regardless of which outcome it measures. The FDA's boxed warning for Cibinqo, shared across the JAK inhibitor class, covers serious infections, mortality, malignancy, major cardiovascular events and thrombosis, per the drug's FDA label. That mortality signal originated in the ORAL Surveillance trial of tofacitinib, a different JAK inhibitor, studied in rheumatoid arthritis patients aged 50 and older with cardiovascular risk factors, not in abrocitinib's own atopic dermatitis trials. The warning nonetheless anchors the age-related caution language on abrocitinib's own label, and Pfizer's integrated long-term safety analysis by age found serious adverse events, serious infections, herpes zoster and cardiovascular events numerically higher in patients 65 and older than in younger patients, particularly at the 200 mg dose, prompting a general steer toward the lower 100 mg dose in older patients, according to coverage in Dermatology Times.

That trial-derived signal sits in tension with at least one smaller real-world cohort. A 57-patient Chinese multicenter retrospective study of patients 65 and older on the 100 mg dose, published in Acta Dermato-Venereologica, reported zero adverse events over 12 weeks, alongside EASI-50 response around 47 percent and EASI-75 around 14 percent by week two, per the paper available on PMC. A short follow-up window, a small sample, and selection bias toward healthier patients who get prescribed a JAK inhibitor at that age could all explain why a 57-patient cohort looks cleaner than an integrated trial dataset spanning thousands. The gap is a reminder that a real-world study's clean safety numbers describe the patients who were selected for the drug, not every patient who might take it.

None of this confirms what the new JAAD paper actually found about appetite, in which direction it changed, how it was measured, whether it tracked with itch relief and improved sleep, or whether it was flagged as a harm. Those details sit behind the paywall, unresolved until the full text or the authors themselves speak to it.